잠시만 기다려 주세요. 로딩중입니다.

Recent Updates of Lipoprotein(a) and Cardiovascular Disease

Chonnam Medical Journal 2021년 57권 1호 p.36 ~ 43
소속 상세정보

Abstract


In recent years, epidemiological studies, genome-wide association studies, and Mendelian randomization studies have shown a strong association between increased levels of lipoproteins and increased risks of coronary heart disease and cardiovascular disease (CVD). Although lipoprotein(a) [Lp(a)] was an independent risk factor for ASCVD, the latest international clinical guidelines do not recommend direct reduction of plasma Lp(a) concentrations. The main reason was that there is no effective clinical medicine that directly lowers plasma Lp(a) concentrations. However, recent clinical trials have shown that proprotein convertase subtilisin/kexin-type 9 inhibitors (PCSK9) and second-generation antisense oligonucleotides can effectively reduce plasma Lp(a) levels. This review will present the structure, pathogenicity, prognostic evidences, and recent advances in therapeutic drugs for Lp(a).

키워드

Atherosclerosis; Lipids; Cardiovascular Diseases

원문 및 링크아웃 정보

 

등재저널 정보